natgillin/translations-raw huggingface dataset:
Plasma concentrations followed a first order absorption process and reached Cmax in approximately 5 hours.
Koncentracije u plazmi slijedile su proces apsorpcije prema kinetici prvog reda i dosegle Cmax za otprilike 5 sati.
• chest pain (not related to the heart)
• bol u prsištu (koja nije povezana sa srcem)
All patients were additionally treated with either doxorubicin (68.0%) or epirubicin (32.0%).
Svi bolesnici bili su dodatno liječeni ili doksorubicinom (68,0%) ili epirubicinom (32,0%).
• you have any other heart problems • you have been told you have an imbalance of minerals in your blood such as potassium and magnesium that has not been corrected.
• rečeno Vam je da imate neravnotežu minerala u krvi kao što su natrij i magnezij, koja nije ispravljena.
The third major metabolite, M2, is > 97% bound to plasma proteins.
Treći glavni metabolit, M2, vezan je za proteine plazme > 97%.
Patients continued into the Multiple-Cycle extension for up to 7 additional cycles of chemotherapy.
Bolesnici su nastavili u produžetku od više ciklusa do 7 dodatnih ciklusa kemoterapije.
• erythromycin - to treat bacterial infections
• eritromicin - za liječenje bakterijskih infekcija
However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.
Međutim, klinički farmakokinetički parametri nisu značajno različiti između slabih i jakih metabolizatora supstrata CYP2D6.
It is not excluded that this effect may be more marked, and then clinically relevant, in cancer patients, notably those having abnormal renal function.
Nije isključeno da ovaj učinak možda bude i izraženiji, a time i klinički značajan u bolesnika s rakom, a osobito onih s poremećenom funkcijom bubrega.
• conjunctivitis (a type of eye inflammation)
• konjunktivitis (vrsta upale oka)
Elimination via both routes was estimated to be complete by Day 29-30 post-dose.
Procijenjeno je da je eliminacija na oba načina završila do 29.30. dana nakon doze.
What Akynzeo is and what it is used for What you need to know before you take Akynzeo How to take Akynzeo
Što je Akynzeo i za što se koristi Što morate znati prije nego počnete uzimati Akynzeo Kako uzimati Akynzeo
• sleep problems
• teškoće sa spavanjem
One 300 mg/0.5 mg capsule should be administered approximately one hour prior to the start of each chemotherapy cycle.
Jednu kapsulu od 300 mg/0,5 mg treba primijeniti otprilike jedan sat prije početka svakog ciklusa kemoterapije.
Breast-feeding should be discontinued during treatment with this medicinal product and for 1 month after the last dose.
Dojenje treba prekinuti tijekom liječenja ovim lijekom i još 1 mjesec nakon zadnje doze.
1 hard capsule 4x1 hard capsules
1 tvrda kapsula 4 x 1 tvrda kapsula
Since it may induce dizziness, somnolence or fatigue, patients should be cautioned not to drive or use machines if such symptoms occur.
Budući da mogu izazvati omaglicu, somnolenciju ili umor, bolesnike treba upozoriti da ne upravljaju vozilima i ne rukuju strojevima ako im se pojave takvi simptomi.
Following oral administration, palonosetron is well absorbed with its absolute bioavailability reaching 97%.
Nakon peroralne primjene, palonozetron se dobro apsorbira uz svoju apsolutnu bioraspoloživost koja doseže 97%.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate,nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
• Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP'.
• Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „Rok valjanosti/EXP“.
Effect of other medicinal products on the pharmacokinetics of Akynzeo
Učinak drugih lijekova na farmakokinetiku Akynzea
• ketoconazole - to treat Cushing's syndrome
• ketokonazol - za liječenje Cushingova sindroma
Alu/Alu blister.
Al/Al blister
• spinning sensation (vertigo), feeling dizzy or trouble sleeping (insomnia)
• vrtoglavica (vertigo), osjećaj omaglice ili teškoće sa spavanjem (nesanica)
A total of 907 patients (62.3%) completed the multiple-cycle extension up to a maximum of eight treatment cycles.
Ukupno 907 bolesnika (62,3%) završilo je produžetak ispitivanja od više ciklusa, do najviše osam ciklusa liječenja.
The ratios were time dependent with values decreasing gradually beyond 24 h post-dose, indicating that netupitant is being rapidly metabolized.
Omjeri su ovisili o vremenu s tim da su se vrijednosti postupno smanjivale nakon više od 24 sata poslije doze, što ukazuje da se netupitant brzo metabolizira.
Erythromycin and Midazolam
Eritromicin i midazolam
The AUC was 30% higher in cancer patients than in healthy subjects.
Vrijednost AUC-a bila je 30% veća u u bolesnika s rakom nego u zdravih ispitanika.
• modifications (or disturbances) in heart rhythm
• promjene (ili poremećaji) srčanog ritma
If you take more Akynzeo than you should
Ako uzmete više Akynzea nego što ste trebali
Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
Palonozetron ima volumen distribucije od približno 8,3 ± 2,5 l/kg.
Studies in animals have shown reproductive toxicity including teratogenic effects in rabbit without safety margin (see section 5.3).
Ispitivanja na životinjama pokazala su reproduktivnu toksičnost, uključujući teratogene učinke u kunića bez granice sigurnosti (vidjeti dio 5.3).
• feeling hot, reddening of the face or other areas of the skin (feeling flushed)
• osjećaj vrućine, crvenilo lica ili drugih područja kože (osjećaj navale crvenila)
Recent guidance has updated these regimens to highly emetogenic.
Novijim smjernicama ovi su protokoli promijenjeni u visoko emetogene.
You may feel dizzy or tired after taking Akynzeo.
Možete osjećati omaglicu ili umor nakon što ste uzeli Akynzeo.
(shown in blood tests)
(prema pretragama krvi)
The significance of these findings in humans is unknown.
Značajnost tih nalaza u ljudi nije poznata.
The underlying mechanisms are not fully understood, but because of the high doses employed and since the medicinal product is intended for single application in humans, these findings are not considered relevant for clinical use.
Osnovni mehanizmi nisu sasvim poznati, ali budući da se radilo o visokim dozama, a ovaj lijek je namijenjen za jednokratnu primjenu u ljudi, ti se nalazi ne smatraju značajnim za kliničku primjenu.
Appropriate observation of patients for serotonin syndrome-like symptoms is advised (see section 4.8).
Savjetuje se odgovarajuće promatranje bolesnika zbog simptoma sličnih serotoninskom sindromu (vidjeti dio 4.8).
The amount of unchanged palonosetron excreted in the urine represented approximately 40% of the administered dose.
Količina nepromijenjenog palonozetrona izlučenog mokraćom predstavljala je približno 40% primijenjene doze.
Akynzeo contains sucrose, sorbitol, sodium and may contain traces of soya.
Akynzeo sadrži saharozu, sorbitol, natrij i može sadržavati tragove soje.
• midazolam - a sedative used to treat anxiety
• midazolam - sedativ koji se koristi za liječenje tjeskobe
In the ADME trial, less than 5% of all netupitant-related material was excreted in urine and less than 1% of the netupitant dose was eliminated unchanged in the urine and therefore any accumulation of netupitant or metabolites after a single dose would be negligible.
U ispitivanju ADME, manje od 5% svih tvari povezanih s netupitantom izlučeno je u mokraći, a manje od 1% doze netupitanta izlučeno je nepromijenjeno u mokraći te bi stoga sva akumulacija netupitanta ili metabolita nakon jedne doze trebala biti zanemariva.
Also tell your doctor, pharmacist or nurse if you are taking any of the following medicines as your doctor may need to change the dose of these other medicines:
Također, obavijestite liječnika, ljekarnika ili medicinsku sestru ako uzimate bilo koji od navedenih lijekova jer Vam liječnik možda treba promijeniti dozu ovih drugih lijekova:
However, due to the large volume of distribution of palonosetron and netupitant, dialysis is unlikely to be an effective treatment for overdose.
Međutim, zbog velikog volumena distribucije palonozetrona i netupitanta, nije vjerojatno da je dijaliza učinkoviti način liječenja predoziranja.
These conditions include patients with a personal or family history of QT prolongation, electrolyte abnormalities, congestive heart failure, bradyarrhythmia, conduction disturbances and in patients taking anti-arrhythmic medicinal products or other medicinal products that lead to QT prolongation or electrolyte abnormalities.
Ova stanja uključuju bolesnike s osobnom ili obiteljskom anamnezom produljenog QT intervala, poremećajem elektrolita, kongestivnim zatajenjem srca, bradiaritmijom, poremećajima provodljivosti te u bolesnika koji uzimaju antiaritmike ili druge lijekove koji dovode do produljenja QT intervala ili poremećaja elektrolita.
If you are not sure, talk to your doctor, pharmacist or nurse before taking this medicine.
Ako niste sigurni, obratite se liječniku, ljekarniku ili medicinskoj sestri prije nego što uzmete ovaj lijek.
Netupitant is not mutagenic.
Netupitant nije mutagen.
Mean Cmax was approximately 11%, 47% and 16% of the parent for M1, M2 and M3 respectively; M2 had the lowest AUC relative to the parent (14%) whereas M1 and M3 AUC were approximately 29% and 33% of the parent, respectively.
Srednja vrijednost Cmax bila je približno 11%, 47% i 16% ishodišnog spoja za M1, M2 odnosno M3; M2 je imao najniži AUC u odnosu na ishodišni spoj (14%) dok su M1 i M3 imali AUC približno 29% odnosno 33% ishodišnog spoja.
These metabolites each have less than 1% of the 5-HT3 receptor antagonist activity of palonosetron.
Svaki od ovih metabolita ima manje od 1% djelovanja palonozetrona kao antagonista receptora 5-HT3.
While the terminal elimination half-life and mean systemic exposure of palonosetron is increased in the subjects with severe hepatic impairment, this does not warrant dose reduction.
Iako su terminalni poluvijek eliminacije i srednja sistemska izloženost palonestronu povećani u ispitanika s teškim oštećenjem jetre, to ne zahtijeva sniženje doze.
The pharmacokinetics of palonosetron or netupitant has not been studied in subjects with end-stage renal disease requiring hemodialysis and no data on the effectiveness or safety of netupitant/palonosetron capsules in these patients are available.
Farmakokinetika palonozetrona ili netupitanta nije ispitana u bolesnika sa završnim stadijem bolesti bubrega kojima je potrebna hemodijaliza, te nema podataka o djelotvornosti ili sigurnosti primjene netupitant/palonozetron kapsula u tih bolesnika.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja fruktoze, malapsorpcijom glukoze i galaktoze ili insuficijencijom sukrazaizomaltaza ne bi smjeli uzimati ovaj lijek.
Pharmacotherapeutic group: Antiemetics and antinauseants, serotonin (5-HT3) antagonists; ATC code: A04AA55
Farmakoterapijska skupina: Antiemetici i lijekovi protiv mučnine, antagonisti serotonina (5-HT3), ATK oznaka: A04AA55
Post-marketing data indicates that the adverse reactions profile is generally similar to that seen in clinical trials.
Podaci dobiveni nakon stavljanja lijeka u promet pokazuju da je profil nuspojava uglavnom sličan onome u kliničkim ispitivanjima.
Because of the antiemetic activity of netupitant and palonosetron, emesis induced by a medicinal product may not be effective.
Zbog antimetičkog djelovanja netupitanta i palonozetrona, emeza potaknuta lijekom možda neće biti učinkovita.
High doses of palonosetron (each dose causing at least 15 times the human therapeutic exposure) applied daily for two years caused an increased rate of liver tumors, endocrine neoplasms (in thyroid, pituitary, pancreas, adrenal medulla) and skin tumors in rats but not in mice.
Visoke doze palonozetrona (svaka doza uzrokovala je izloženost najmanje 15 puta veću od terapijske izloženosti u čovjeka) primijenjene svakodnevno tijekom dvije godine, uzrokovale su povećanu stopu tumora jetre, neoplazmi endokrinog sustava (u štitnjači, hipofizi, gušterači, moždini nadbubrežnih žlijezda) i tumora kože u štakora, ali ne u miševa.
In female subjects (n=18), the mean AUC was 35% higher and the mean Cmax was 26% higher than in male subjects (n=18).
U žena (n = 18), srednja vrijednost AUC-a bila je 35% viša, a srednja vrijednost Cmax 26% viša nego u muškaraca (n = 18).
Women of childbearing potential should not be pregnant or become pregnant while on treatment with netupitant/palonosetron capsules.
Žene reproduktivne dobi ne smiju biti trudne ili zatrudnjeti dok se liječe netupitant/palonozetron kapsulama.
Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S-hydroxy-palonosetron.
Palonozetron se eliminira višestrukim putevima, s tim da se približno 50% metabolizira i tvori dva primarna metabolita: N-oksid-palonozetron i 6-S-hidroksi-palonozetron.
Other medicines and Akynzeo
Drugi lijekovi i Akynzeo
Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.
Palonozetron je antagonist receptora 5-HT3, koji ima veliki afinitet vezanja za taj receptor, a mali ili nikakav afinitet za druge receptore.
This medicine contains sucrose, sorbitol, sodium and may contain soya - see section 2 for more information.
Ovaj lijek sadrži saharozu, sorbitol i natrij te može sadržavati soju - za više informacija pogledajte dio 2.
Palonosetron 0.5 mg
Palonozetron 0,5 mg
Primary endpoint Complete response Overall phase Major secondary endpoints Complete response Acute phase Delayed phase No emesis Acute phase Delayed phase Overall phase No significant nausea Acute phase Delayed phase Overall phase Acute phase: 0 to 24 hours post-cisplatin treatment.
Primarni ishod Potpuni odgovor Cijela faza Glavni sekundarni ishodi Potpuni odgovor Akutna faza Odgođena faza Bez emeze Akutna faza Odgođena faza Cijela faza Bez značajne mučnine Akutna faza Odgođena faza Cijela faza Akutna faza: od 0 do 24 sata poslije terapije cisplatinom.
Acute psychosis Mood altered Sleep disorder
Psihijatrijski poremećaji nesanica akutna psihoza promijenjeno raspoloženje poremećaj spavanja
Maximum concentrations and total exposure of netupitant were increased in subjects with mild (n=8), moderate (n=8), and severe (n=2) hepatic impairment compared to matching healthy subjects, although there was pronounced individual variability in both hepatically-impaired and healthy subjects.
Maksimalna koncentracija i ukupna izloženost netupitantu bile su povećane u ispitanika s blagim (n = 8), umjerenim (n = 8) i teškim (n = 2) oštećenjem funkcije jetre u usporedbi s podudarnim zdravim ispitanicima, iako je postojala naglašena individualna varijabilnost i u ispitanika s oštećenjem funkcije jetre i u zdravih ispitanika.
In a study performed in healthy volunteers, netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by 1.09 fold [90%CI 0.9-1.31].
Prema ispitivanju provedenom u zdravih dobrovoljaca, netupitant ne utječe na izloženost digoksinu, supstratu P-gp-a, ali povećava njegov Cmax za 1,09 puta [90% CI 0,9-1,31].
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these active substances with netupitant/palonosetron capsules.
Mogući učinci povećanih plazmatskih koncentracija midazolama ili drugih benzodiazepina metaboliziranih putem CYP3A4 (alprazolam, triazolam) moraju se uzeti u obzir kada se te djelatne tvari primjenjuju istovremeno s netupitant/palonozetron kapsulama.
The signs may include tremor, agitation, sweating, myoclonic movements, hypertonia and fever.
Znakovi mogu uključivati tremor, agitaciju, znojenje, mioklonične pokrete, hipertoniju i vrućicu.
The medicines in Akynzeo attach to the receptors in the nervous system through which serotonin and substance P work: netupitant (an NK1 receptor antagonist) blocks the receptors for substance P, and palonosetron (a 5HT3 receptor antagonist) blocks certain receptors for serotonin.
Lijekovi u Akynzeu vežu se na receptore u živčanom sustavu kroz koje djeluju serotonin i tvar P: netupitant (antagonist receptora NK1) blokira receptore za tvar P, a palonozetron (antagonist receptora 5-HT3) blokira određene receptore za serotonin.
Phospholipidosis (foamy macrophages) has been observed with the administration of netupitant after repeated administration in rats and dogs.
Fosfolipidoza (pjenasti makrofazi) opažena je uz primjenu netupitanta nakon ponavljane primjene u štakora i pasa.
• some chemotherapy medicines - such as docetaxel or etoposide
• neke kemoterapijske lijekove - kao što su docetaksel ili etopozid
Based on the experience with healthy subjects exposed to oral netupitant 600 mg in combination with palonosetron 1.50 mg the potential acute symptoms of overdose are headache, dizziness, constipation, anxiety, palpitations, euphoric mood and pain in the legs.
Na temelju iskustva sa zdravim ispitanicima koji su bili izloženi peroralnom netupitantu u dozi od 600 mg u kombinaciji s palonozetronom od 1,50 mg, mogući akutni simptomi predoziranja su glavobolja, omaglica, konstipacija, anksioznost, palpitacije, euforično raspoloženje i bolovi u nogama.
Serotonergic medicinal products (e.g. SSRIs and SNRIs)
Serotoninergički lijekovi (npr. SSRI i SNRI)
• The other ingredients are microcrystalline cellulose (E460), sucrose lauric acid esters, povidone K-30, croscarmellose sodium, colloidal hydrated silica, sodium stearyl fumarate, magnesium stearate, glycerol monocaprylocaproate (type I), glycerol, polyglyceryl oleate, purified water, butylhydroxyanisole (E320), gelatin, sorbitol, 1,4 sorbitan, titanium dioxide (E171), shellac glaze (partially esterified), yellow, red and black iron oxide (E172), propylene glycol (E1520).
• Drugi sastojci su mikrokristalična celuloza (E460), saharozni esteri lauratne kiseline, povidon K-30, umrežena karmelozanatrij, koloidni hidratizirani silicijev dioksid, natrijev stearilfumarat, magnezijev stearat, glicerolmonokaprilokaprat (vrsta I), glicerol, poligliceriloleat, pročišćena voda, butilhidroksianizol (E320), želatina, sorbitol, 1,4 sorbitan, titanijev dioksid (E171), šelakova glazura (djelomično esterificirana), žuti, crveni i crni željezov oksid (E172), propilenglikol (E1520).
Netupitant/palonosetron capsules, when given with a single oral dose of 60 μg ethinylestradiol and 300 μg levonorgestrel had no significant effect on the AUC of ethinylestradiol and increased the AUC of levonorgestrel by 1.4-fold; clinical effects on the efficacy of hormonal contraception are unlikely.
Kad su se netupitant/palonozetron kapsule davale s jednom peroralnom dozom od 60 μg etinilestradiola i 300 μg levonorgestrela, nisu imale značajan učinak na AUC etinilestradiola i povećale su AUC levonorgestrela za 1,4 puta; klinički učinci na djelotvornost hormonskih kontraceptiva nisu vjerojatni.
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Akynzeo.
Ako se nešto od gore navedenog odnosi na Vas (ili niste sigurni), obratite se liječniku, ljekarniku ili medicinskoj sestri prije nego što uzmete Akynzeo.
moxifloxacin, haloperidol, chlorpromazine, quetiapine, thioridazine or domperidone
kinidin, moksifloksacin, haloperidol, klorpromazin, kvetiapin, tioridazin ili domperidon
• palonosetron.
• palonozetron.
Caution should be exercised in patients with severe hepatic impairment since limited data are available in these patients.
Potreban je oprez u bolesnika s teškim oštećenjem funkcije jetre jer su podaci u tih bolesnika ograničeni.
• coating of the tongue, difficulty swallowing, dry mouth, belching, abnormal taste after medicine intake
• obložen jezik, otežano gutanje, suha usta, podrigivanje, neprirodan okus nakon uzimanja lijeka
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na trudnoću, razvoj embrija/fetusa, parturiciju ili postnatalni razvoj.
However, since netupitant/palonosetron capsules contains a 5-HT3 receptor antagonist, caution should be exercised in concomitant use with medicinal products that increase the QT interval or in patients who have or are likely to develop prolongation of the QT interval.
Međutim, budući da netupitant/palonozetron kapsule sadrže antagonist receptora 5-HT3, potreban je oprez kad se istovremeno primjenjuju lijekovi koji produljuju QT interval ili u bolesnika koji imaju ili u kojih bi se moglo razviti produljenje QT intervala.
Serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.
Serotonin zatim aktivira receptore 5HT3 smještene na vagusnim aferentnim vlaknima, čime se pobuđuje refleks povraćanja.
Titanium dioxide (E171)
1,4 sorbitan titanijev dioksid (E171)
• medicines that might cause abnormal heartbeat such as amiodarone, nicardipine, quinidine,
• lijekove koji mogu prouzročiti nepravilne srčane otkucaje kao što su amiodaron, nikardipin,
Three metabolites have been detected in human plasma at netupitant oral doses of 30 mg and higher (the desmethyl derivative, M1; the N-oxide derivative, M2; the OH-methyl derivative, M3).
Kod peroralnih doza netupitanta od 30 mg i više, u ljudskoj plazmi otkrivena su tri metabolita (dezmetil derivat, M1; N-oksid derivat, M2; OH-metil derivat, M3).
Co-administration of a single dose of 300 mg netupitant with a dexamethasone regimen (20 mg on Day 1, followed by 8 mg twice daily from Day 2 to Day 4) significantly increased the exposure to dexamethasone in a time and dose dependent manner.
Istovremena primjena jedne doze netupitanta od 300 mg s režimom deksametazona (20 mg 1. dana, a zatim 8 mg dvaput na dan od 2. do 4. dana) značajno je povećala izloženost deksametazonu na način ovisan o vremenu i dozi.
The proportion of patients with Overall no impact on daily life was 6.3% higher (p value =0.005) in the Akynzeo group (78.5%) than in the palonosetron group (72.1%).
Udio bolesnika bez sveukupnog utjecaja na svakodnevni život bio je 6,3% veći (p-vrijednost = 0,005) u skupini koja je primala Akynzeo (78,5%) nego u skupini koja je primala palonozetron (72,1%).
Human plasma protein binding of netupitant and its two major metabolites M1 and M3 is > 99% at concentrations ranging from 10 to 1500 ng/mL.
Vezanje netupitanta te njegovih dvaju glavnih metabolita M1 i M3 na proteine u ljudskoj plazmi iznosi > 99% pri koncentracijama u rasponu od 10 do 1500 ng/ml.
No dosage adjustment is necessary for patients with mild or moderate hepatic impairment (ChildPugh score 5-8).
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child Pugh rezultat 5-8).
Degeneration of seminiferous epithelium was associated with palonosetron following a one month oral repeat dose toxicity study in rats.
Degeneracija sjemenskog epitela bila je povezana s palonozetronom nakon mjesec dana ispitivanja toksičnosti ponovljenih peroralnih doze u štakora.
Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects.
Oštećenje jetrene funkcije ne utječe značajno na ukupni tjelesni klirens palonozetrona u usporedbi sa zdravim ispitanicima.
The hard capsules are opaque with a white body and a caramel cap with ‘HE1' printed on the body.
Tvrde kapsule su neprozirne s bijelim tijelom i kapicom boje karamele, s oznakom „HE1“ otisnutom na tijelu.
• decreased blood flow to the heart muscle (myocardial ischemia)
• smanjeni dotok krvi u srčani mišić (ishemija miokarda)
Chemotherapeutic substances produce nausea and vomiting by stimulating the release of serotonin from the enterochromaffin cells of the small intestine.
Kemoterapijske tvari uzrokuju mučninu i povraćanje stimulacijom otpuštanja serotonina iz enterokromafinih stanica tankog crijeva.